Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, 03756, United States
NCT Number: NCT02159157
This study is designed to randomly assign breast cancer patients requiring and agreeing to chemotherapy into two groups. One group will be receive an exercise prescription aimed at increasing physical activity by a minimum of 10 MET (metabolic equivalent task) hours per week. The other group will not receive a exercise prescription but their activity will be recorded. The hypothesis is that participants that are most active will exhibit improved chemotherapy completion rates, improved fitness, less fatigue and lower levels of markers for inflammation in their blood.
Looking for future studies?
Notify Me18 year–99 year
All sexes
Interventional
Not applicable
Lebanon, New Hampshire, 03756, United States
This is a prospective, randomized, single institution feasibility trial. The efficacy of an exercise intervention during chemotherapy for sedentary breast cancer patients will be tested. The investigators goal is to recruit 120 women and men. Assuming 20% attrition rate, 96 will be randomized to two arms, comparing patients assigned to a physical activity program plus general health education materials versus patients assigned to receive standard general health education materials only. Study measures will be obtained before intervention, at 24 weeks, and at the end of the intervention, approximately week 32.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
Time frame: from baseline to week 32
A log will be used to record patient's exercise activity and pedometer data on a weekly and monthly basis.
Time frame: 32 weeks
The RDI is calculated by (delivered dose)/(standard dose) x 100. Delivered dose = (actual total dose in mg/m2)/ (total days required to complete the treatment) Standard dose = (recommended total dose) / (total days planned to complete the treatment)
Time frame: baseline (Day -28 to 1), week 24, 32 weeks
Fatigue as measured by the FACIT-F survey
Time frame: baseline (Day -28 to 1), 32 weeks
Time frame: Baseline (day -28 to day 1) and week 32
levels of C- reactive protein
Time frame: Baseline (day -28 to day 1) and week 32
Fasting insulin levels measured in blood at baseline (day -28 to day 1) and week 32
Time frame: baseline (day -28 to day 1) and week 32
Time frame: baseline (day -28 to day 1) and week 32
Time frame: baseline (day -28 to day 1) and week 32
Time frame: baseline (day -28 to day 1) and week 32
Time frame: weekly for 32 weeks
Average steps per week for weeks 1-32
Time frame: From baseline to Week 32
How the participant is feeling about the exercise.
Dartmouth-Hitchcock Medical Center
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07521397
Adjuvant Chemotherapy, Breast Cancer
Athens, Greece
View Trial DetailsNCT02335671
Breast Cancer Stage I, Breast Cancer Stage II
Boston, Massachusetts, United States
View Trial DetailsNCT00309569
Breast Diseases, Breast Neoplasms
View Trial DetailsNCT01871116
Body Weight, Body Weight Changes
Baltimore, Maryland, United States
View Trial Details